About: NicVAX

An Entity of Type: drug, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

NicVAX is an experimental conjugate vaccine intended to reduce or eliminate physical dependence to nicotine. According to the U.S. National Institute of Drug Abuse, NicVAX can potentially be used to inoculate against nicotine addiction. This proprietary vaccine is being developed by Nabi Biopharmaceuticals of Rockville, MD. with the support from the U.S. National Institute on Drug Abuse. NicVAX consists of the hapten 3'-aminomethylnicotine which has been conjugated (attached) to Pseudomonas aeruginosa exotoxin A.

Property	Value
dbo:abstract	NicVAX is an experimental conjugate vaccine intended to reduce or eliminate physical dependence to nicotine. According to the U.S. National Institute of Drug Abuse, NicVAX can potentially be used to inoculate against nicotine addiction. This proprietary vaccine is being developed by Nabi Biopharmaceuticals of Rockville, MD. with the support from the U.S. National Institute on Drug Abuse. NicVAX consists of the hapten 3'-aminomethylnicotine which has been conjugated (attached) to Pseudomonas aeruginosa exotoxin A. Early trials of NicVax were promising; two successive phase III trials showed results no better than placebo, and a more recent study showed that the drug decreased subjects' cravings for cigarettes. (en)
dbo:wikiPageID	6818170 (xsd:integer)
dbo:wikiPageLength	11802 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1121961365 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Molecule dbr:Bloodstream dbr:Upper_respiratory_tract dbr:Inoculation dbr:Smoking_cessation dbc:Smoking dbr:Common_cold dbr:Pseudomonas_aeruginosa dbr:Conjugate_vaccine dbr:Antibody dbr:Clinical_Pharmacology_&_Therapeutics dbr:Physical_dependence dbc:Vaccines_against_drugs dbr:Nicotine dbr:Norepinephrine dbr:Central_nervous_system dbr:Hapten dbr:Receptor_(biochemistry) dbr:Headache dbr:Blood–brain_barrier dbr:Dopamine dbr:Placebo dbr:Immunoglobulin dbr:Injection_(medicine) dbr:Antibodies dbr:Immune_response dbr:Immune_system dbr:Exotoxin_A dbr:U.S._National_Institute_of_Drug_Abuse dbr:U.S._National_Institute_on_Drug_Abuse
dbp:wikiPageUsesTemplate	dbt:Cleanup_bare_URLs dbt:Reflist dbt:Short_description dbt:Vaccines
dcterms:subject	dbc:Smoking dbc:Vaccines_against_drugs
gold:hypernym	dbr:Vaccine
rdf:type	yago:WikicatVaccines yago:Antigen115037339 yago:Immunogen103562739 yago:Matter100020827 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 yago:Vaccine104517535
rdfs:comment	NicVAX is an experimental conjugate vaccine intended to reduce or eliminate physical dependence to nicotine. According to the U.S. National Institute of Drug Abuse, NicVAX can potentially be used to inoculate against nicotine addiction. This proprietary vaccine is being developed by Nabi Biopharmaceuticals of Rockville, MD. with the support from the U.S. National Institute on Drug Abuse. NicVAX consists of the hapten 3'-aminomethylnicotine which has been conjugated (attached) to Pseudomonas aeruginosa exotoxin A. (en)
rdfs:label	NicVAX (en)
owl:sameAs	freebase:NicVAX wikidata:NicVAX https://global.dbpedia.org/id/54Jq9 yago-res:NicVAX
prov:wasDerivedFrom	wikipedia-en:NicVAX?oldid=1121961365&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:NicVAX
is dbo:wikiPageRedirects of	dbr:NicVax dbr:3′AmNic-rEPA
is dbo:wikiPageWikiLink of	dbr:Smoking_cessation dbr:Conjugate_vaccine dbr:Immunization dbr:NicVax dbr:3′AmNic-rEPA
is foaf:primaryTopic of	wikipedia-en:NicVAX

This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License